Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 12/20 | 0.83 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.39 |
| ▸ | KAT7 | O95251 | 4/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.36 |
| ▸ | KAT6B | Q8WYB5 | 3/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1478871 | 0.91 | KCNA5 (1.00) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1477965 | 0.89 | KCNA5 (0.79) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1480514 | 0.81 | KCNA5 (0.73) | KCNA5KAT7KAT6AKAT6BKAT5 | |
| SCHEMBL1478047 | 0.80 | KCNA5 (0.69) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1480481 | 0.80 | KCNA5 (0.72) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1480539 | 0.79 | KCNA5 (0.67) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1478284 | 0.78 | KCNA5 (0.66) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1478165 | 0.77 | KCNA5 (0.75) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL1478128 | 0.77 | KCNA5 (0.75) | KCNA5SGMS2SGMS1KAT7KAT6A | |
| SCHEMBL14644962 | 0.76 | KCNA5 (0.73) | KCNA5KAT7KAT6AKAT6BKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357809-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915410-B2 | Acyclic IKur inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | KCNA5 67/4885SGMS2 3812/4885TP53 3042/4885 |
| US-20120094983-A1 | ACYCLIC IKUR INHIBITORS | KCNH2, KCNJ2, KCNH3 | KCNA5 67/4885SGMS2 3812/4885TP53 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.